Introduction
============

Lung cancer (LC) is one of the most common malignant tumors in the world ([@b1-ijo-54-05-1651],[@b2-ijo-54-05-1651]). According to data compiled by the American Cancer Society, there were 234,030 estimated new LC cases and 154,050 estimated LC-associated mortalities in the USA in 2018 ([@b3-ijo-54-05-1651]). In terms of histology, there are two types of LC: Non-small cell LC (NSCLC) and small cell LC, of which the former makes up 85% of all cases ([@b4-ijo-54-05-1651]). NSCLC is comprised of two subtypes: Lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD) ([@b3-ijo-54-05-1651],[@b5-ijo-54-05-1651]). Drugs targeting mutated versions of the epidermal growth factor receptor (EGFR), GTPase KRas and ALK tyrosine kinase receptor proteins mutations have already demonstrated beneficial effects in patients with LUAD ([@b6-ijo-54-05-1651]). However, these drugs are not applicable to LUSC, which is associated with poor survival rates ([@b7-ijo-54-05-1651]), highlighting the urgent requirement for effective diagnostic and therapeutic targets for LUSC.

Long non-coding RNAs (lncRNAs) are a class of non-protein-coding RNAs that control gene expression in complex ways ([@b8-ijo-54-05-1651],[@b9-ijo-54-05-1651]). Numerous studies have revealed that the ectopic expression of lncRNAs is implicated in human cancer ([@b10-ijo-54-05-1651]-[@b13-ijo-54-05-1651]). As a member of the lncRNA family, the cancer susceptibility candidate 9 (CASC9) gene, located on chromosome 8q21.11, was originally observed to be upregulated in esophageal squamous cell carcinoma (ESCC) ([@b14-ijo-54-05-1651]). In addition, CASC9 was reported to constitute a crucial component in the tumorigenesis of other types of cancer, including gastric and nasopharyngeal cancer ([@b15-ijo-54-05-1651],[@b16-ijo-54-05-1651]). With regard to NSCLC, recent studies have discovered that CASC9 was associated with the resistance of NSCLC cells to EGFR tyrosine kinase inhibitors, and that it served important roles in the proliferation and metastasis of LUAD cells ([@b17-ijo-54-05-1651],[@b18-ijo-54-05-1651]). Although studies on CASC9 in NSCLC have reported promising results, they have mainly focused on LUAD, and studies on the role of CASC9 in LUSC are lacking.

In the present study, the clinicopathological effect of CASC9 in LUSC was investigated using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and data mining of public databases, including The Cancer Genome Atlas (TCGA), the Gene Expression Omnibus (GEO), ArrayExpress, and the Cancer Cell Line Encyclopedia (CCLE). Furthermore, the functional influence of CASC9 on LUSC, and the underlying mechanism, were explored through *in vitro* experiments, investigation of the mutation status of CASC9 in LUSC from cBioPortal, functional enrichment analysis of co-expressed genes using Gene Expression Profiling Interactive Analysis (GEPIA), prediction of potential transcription factors, and inspection of adjacent protein-coding genes. The design of the current study is illustrated in [Fig. 1](#f1-ijo-54-05-1651){ref-type="fig"}.

Materials and methods
=====================

Tissue samples
--------------

A total of 20 patients first diagnosed with LUSC (age range, 35-68 years; mean, 51 years; 12 male and 8 female) attending the First Affiliated Hospital of Guangxi Medical University (Nanning, China) were included in the present study. The patients were receiving no medication and underwent radical resection of lung cancer between August 2017 and March 2018. Tumor and matched non-cancer lung tissues were obtained from these patients during the radical resection surgery. The samples were fixed in 10% buffered formalin under ambient temperature for 16 h and paraffin-embedded. All patients provided signed informed consent and approval of this study was granted by the Ethics Committee of the First Affiliated Hospital of Guangxi Medical University.

RT-qPCR
-------

The isolation and relative quantification of RNA was conducted based on methods described previously ([@b19-ijo-54-05-1651]). RT and qPCR kits were used to examine the CASC9 expression levels in LUSC and adjacent non-cancer tissues, following the manufacturers\' protocols. qPCR was performed on an ABI 7900 Real-time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA) using the LightCycler^®^ FastStart DNA Master plus SYBR Green kit (Roche Diagnostics, Basel, Switzerland). The denaturation, annealing and extension steps of the 40 PCR cycles were set at 95°C for 10 sec, 60°C for 5 sec and 72°C for 5 sec, following a 10-min hot start at 95°C. The primers for CASC9 and the reference gene GAPDH were as follows: CASC9 forward, 5′-AAAACCAGGTGGGACCCAGA-3′; reverse, 5′-TGATCAGAAGAAGAGGGGCA-3′; GAPDH forward, 5′-ACCCACTCCTCCACCTTTG-3′; and reverse, 5′-CTCTTGTGCTCTTGCTGGG-3′. CASC9 expression was calculated according to the formula: 2^−ΔCq=^ 2^−(CqCASC9-CqGAPDH)^, where the Cq value is the quantification cycle number ([@b20-ijo-54-05-1651]).

Evaluation of the clinicopathological associations of CASC9 in LUSC, using TCGA data
------------------------------------------------------------------------------------

TCGA (<http://cancergenome.nih.gov/>), an extensive reservoir of DNA methylation, exome sequencing, single nucleotide polymorphism array, RNA-seq and microRNA-seq data ([@b21-ijo-54-05-1651],[@b22-ijo-54-05-1651]), assists researchers in conducting studies using complicated cancer genomics profiles. In the present study, log~2~(x+1)-transformed level 3 transcripts per million reads (TPM) RNA-seq data of CASC9 expression in 501 LUSC and 49 adjacent normal tissues as well as the clinicopathological data of the 501 patients from whom the samples were obtained (TCGA-LUSC), were collected from TCGA data portal (<https://portal.gdc.cancer.gov/>) and analyzed using SPSS version 22.0 (IBM Corp., Armonk, NY, USA).

Integrated meta-analysis of CASC9 expression in LUSC and non-cancer tissues
---------------------------------------------------------------------------

To comprehensively appraise the differential expression of CASC9 in LUSC and non-cancer tissues, expression data of CASC9 in LUSC and non-cancer tissues published before September 19, 2018 were searched in the GEO (<https://www.ncbi.nlm.nih.gov/gds/>), ArrayExpress (<https://www.ebi.ac.uk/arrayexpress/>) and literature databases, including Pubmed (<https://www.ncbi.nlm.nih.gov/pubmed>), Google Scholar (<https://scholar.google.com/>), Wiley Online Library (<https://onlinelibrary.wiley.com/>), Cochrane Library (<https://www.cochranelibrary.com/library>), Web of Science (<http://apps.webofknowledge.com>), Embase (<https://www.embase.com>), Ebsco (<https://www.ebsco.com/>), Chinese VIP (<http://www.cqvip.com/>), China National Knowledge Infrastructure (<http://www.cnki.net/>), Sinomed (<http://www.sinomed.ac.cn/>) and Wang Fang (<http://www.wanfangdata.com.cn/index.html>). The search terms used in the GEO were: (\'Lung neoplasms\'\[Mesh\]) AND (\'microarray analysis\'\[Mesh\] OR \'tissue array analysis\'\[Mesh\] OR \'transcriptome\'\[Mesh\] OR \'sequence analysis, RNA\'\[Mesh\] OR \'high-throughput nucleotide sequencing\'\[Mesh\]). The key words for searching in ArrayExpress were: (\'Cancer\' OR \'carcinoma\' OR \'adenocarcinoma\' OR \'tumour\' OR \'tumor\' OR \'malignanc\*\' OR \'neoplas\*\') AND (\'lung\' OR \'pulmonary\' OR \'respiratory\' OR \'respiration\' OR \'aspiration\' OR \'bronchi\' OR \'bronchioles\' OR \'alveoli\' OR \'pneumocytes\' OR \'air way\'). Regarding the literature survey, the search terms used were as follows: (\'CASC9\' OR \'cancer susceptibility 9\' OR \'ESSCAL1\' OR \'ESCCAL-1\' OR \'LINC0098\') AND (\'lung\' OR \'pulmonary\' OR \'respiratory\' OR \'respiration\' OR \'aspiration\' OR \'bronchi\' OR \'bronchioles\' OR \'alveoli\' OR \'pneumocytes\' OR \'air way\') AND (\'cancer\' OR \'carcinoma\' OR \'adenocarcinoma\' OR \'tumour\' OR \'tumor\' OR \'malignanc\*\' OR \'neoplas\*\'). Studies using human-derived samples offering sufficient CASC9 expression data (where the numbers of LUSC and non-cancer cases exceeded 3) in LUSC and non-cancer samples for the calculation of a standardized mean difference (SMD) were included. Basic information, as well as expression and diagnostic data, including accession ID, first author, publication year, country, experiment type, sample type, platform, number of cases in the cancer or non-cancer groups, mean ± SD of CASC9 expression in the cancer or non-cancer groups, true positives, false positives, false negatives and true negatives, were extracted from the included studies according to methods described previously ([@b23-ijo-54-05-1651]). An SMD with the 95% confidence interval (CI) and summarized receiver operating characteristic (SROC) curves were produced for the integrated meta-analysis, consisting of the in-house RT-qPCR data, TCGA data and microarray chip data from ArrayExpress, as described previously ([@b23-ijo-54-05-1651]).

Cell line data of CASC9 expression from CCLE
--------------------------------------------

The expression data of CASC9 in all available LC cell lines was downloaded from CCLE (<https://portals.broadinstitute.org/ccle/about>) on October 5, 2018. The original data included 192 LC cell lines. Due to contamination or misidentification of the PC-14 cell line being reported by the International Cell Line Authentication Committee, Database of Cross-Contaminated or Misidentified Cell Lines (<http://iclac.org/databases/cross-contaminations/>), it was excluded from the present expression analysis. Finally, the expression data of CASC9 from a total of 191 cell lines were merged into a heat map using GraphPad Prism 7 (GraphPad Software, Inc., La Jolla, CA, USA).

Cell transfection and in vitro experiments
------------------------------------------

The human LUSC H226 cells were purchased from the American Type Culture Collection (Manassas, VA, USA), cultured in Dulbecco\'s modified Eagle\'s medium (Gibco; Thermo Fisher Scientific, Inc.) and supplemented with 10% fetal bovine serum (Biological Industries, Kibbutz Beit Haemek, Israel) and penicillin-streptomycin at 37°C under a humidified atmosphere of 5% CO~2~. Each *in vitro* experiment was performed in triplicate. The H226 cells were seeded into 96-well plates, at 2.5×10^3^ cells per well, and incubated at 37°C for 24 h prior to transfection. Transfections of mock control, scrambled small interfering (si)RNAs, and CASC9 siRNAs (Ambion; Thermo Fisher Scientific, Inc.) were performed in H226 cells at a concentration of 200 nM for 96 h using the CombiMag Magnetofection™ transfection kit (OZBiosciences SAS, Marseille, France), according to the manufacturer\'s protocol. The siRNAs were designed for the best efficiency to knockdown CASAC9 using the online tool InvivoGen siRNA Wizard Software version 3.1 (<https://www.invivogen.com/sirnawizard/index.php>), and 4 siRNAs were finally selected. Scrambled siRNAs were included to serve as negative controls for each of these. The siRNAs sequences are listed in [Table SI](#SD1-ijo-54-05-1651){ref-type="supplementary-material"}. The 4 selected CASC9 siRNAs were pooled for use in subsequent experiments, as were the scrambled siRNAs. To investigate the influence of CASC9 on the viability and proliferation of H226 cells, fluorimetric resorufin viability and MTS tetrazolium assays were conducted as described previously ([@b24-ijo-54-05-1651]-[@b27-ijo-54-05-1651]).

cBioPortal gene alteration of CASC9 in LUSC tissue
--------------------------------------------------

The gene alteration status of CASC9 in LUSC (dataset TCGA, provisional) was acquired from cBioPortal version 2.0.1 (<http://www.cbioportal.org>) ([@b28-ijo-54-05-1651]). The distribution of the CASC9 alteration in 179 sequenced patients with LUSC was visualized using the OncoPrint module of cBioPortal.

Functional enrichment analysis of co-expressed genes
----------------------------------------------------

Genes co-expressed with CASC9 were identified from the GEPIA. The biological functions of the co-expressed genes were investigated via the enrichment annotation modules in Metascape (<http://metascape.org>) (Kyoto Encyclopedia of Genes and Genomes Pathway, GO Biological Processes, Reactome Pathway Database, Canonical Pathways, and CORUM). Terms with P\<0.01 and the number of enriched genes \>3 were considered to be significantly associated with the genes.

Prediction of potential transcription factors for CASC9
-------------------------------------------------------

Potential transcription factors associated with CASC9 were identified by referring to a series of databases, including starBase (<http://starbase.sysu.edu.cn/>), TransmiR (<http://www.cuilab.cn/transmir>), TRED (<http://rulai.cshl.edu/TRED>), ITFP (<https://omictools.com/itfp-tool>), TFe (<http://www.cisreg.ca/tfe>), AnimalTFDB (<http://bioinfo.life.hust.edu.cn/AnimalTFDB/>) and LncMAP (<http://bio-bigdata.hrbmu.edu.cn/LncMAP/>). HT-Seq TPM RNA-seq data of predicted transcription factors in LUSC were downloaded from TCGA, and Pearson\'s correlation analysis was performed in GraphPad Prism 7 to evaluate the correlation between them and CASC9 expression.

Correlations between CASC9 and adjacent protein-coding genes
------------------------------------------------------------

Protein-coding genes adjacent to CASC9 were searched using the Ensemble Genome Browser (<http://grch37.ensembl.org/index.html>) and the HT-Seq TPM RNA-seq data of these genes in LUSC were downloaded from TCGA. The association between CASC9 expression and that of the identified adjacent protein-coding genes was analyzed by Pearson\'s correlation tests in GraphPad Prism 7.

Statistical analysis
--------------------

The statistical analyses for the RT-qPCR and TCGA data were performed in SPSS version 22.0. The expression values of CASC9 in LUSC and non-cancer tissues are presented as the mean ± SD. Paired t-tests were conducted to compare the expression of CASC9 between LUSC and non-cancer tissues, as derived from the RT-qPCR assays. Regarding the clinicopathological effect of CASC9 expression in LUSC from TCGA data, the Mann-Whitney test was employed to evaluate the differential expression of CASC9 in two subgroups of clinicopathological variables. When a clinicopathological variable contained \>3 subgroups, the Kruskal-Wallis test was performed. To assess the ability of CASC9 to distinguish LUSC from non-cancer tissue, ROC curves were created. The discernment capacity of CASC9 for LUSC increased with the area under the curves (AUC) varying from 0.5-1.0. The impact of high versus low CASC9 expression (divided by the average CASC9 expression value) on the survival rate of patients with LUSC was evaluated using the Kaplan-Meier survival curves. Multivariate Cox regression analysis was performed to judge whether CASC9 expression could serve as a prognostic indicator for LUSC independent of clinical variables. Two-way analysis of variance and Bonferroni post-tests were performed for the comparison of the groups in the fluorimetric resorufin viability and MTS tetrazolium assays. P\<0.05 was considered to indicate statistically significant differences.

Results
=======

RT-qPCR
-------

[Fig. 2](#f2-ijo-54-05-1651){ref-type="fig"} illustrates the finding that the expression level of CASC9 in LUSC tissues (relative expression, 2.771±0.974) was significantly higher than that in paired, non-cancer tissues (relative expression, 1.397±0.857) (P\<0.001; [Fig. 2A](#f2-ijo-54-05-1651){ref-type="fig"}). ROC curves with an AUC value of 0.855 indicated the diagnostic ability of CASC9 expression levels to distinguish LUSC tissues from non-cancer tissues (P\<0.001; [Fig. 2A](#f2-ijo-54-05-1651){ref-type="fig"}, right panel).

Evaluation of the clinicopathological influence of CASC9 in LUSC from TCGA data
-------------------------------------------------------------------------------

Compared with adjacent normal lung tissue, CASC9 was significantly upregulated in LUSC tissue (relative expression, 0.190±0.282 vs. 4.420±1.528; P\<0.001; [Fig. 2B](#f2-ijo-54-05-1651){ref-type="fig"}). Apart from the differential expression between LUSC and normal tissue, overexpression of CASC9 in LUSC was observed to be significantly associated with several clinicopathological parameters of LUSC, including sex (P=0.029), clinical stage (P\<0.001), distant metastasis (P=0.004) and lymph node metastasis (P=0.039) ([Table I](#tI-ijo-54-05-1651){ref-type="table"}). Male patients and patients with advanced clinical stage (III-IV), distant metastasis and lymph node metastasis exhibited notably higher expression of CASC9. No significant associations were observed between the expression levels of CASC9 and other clinicopathological variables. The ROC curves in [Fig. 2](#f2-ijo-54-05-1651){ref-type="fig"} suggest that the measurement of CASC9 performed well in discriminating LUSC from normal tissue (AUC=0.960; P\<0.001). There was no significant difference between the survival rates of patients divided into high- and low-expression groups according to the average CASC9 expression value (P=0.189; [Fig. S1](#SD1-ijo-54-05-1651){ref-type="supplementary-material"}) and the multivariate Cox regression analysis revealed that age (HR, 0.480; 95% CI, 0.269-0.855; P=0.013) and tumor location (HR, 1.850; 95% CI, 1.080-3.169; P=0.025) were independent prognostic factors for LUSC ([Table II](#tII-ijo-54-05-1651){ref-type="table"}).

Integrated meta-analysis for the expression difference of CASC9 between LUSC and non-cancer tissue
--------------------------------------------------------------------------------------------------

A total of 2,921 and 1,860 studies were identified in the initial searches in GEO and ArrayExpress, respectively. Of these, 85 GEO microarray chips and 9 ArrayExpress chips were included following the scanning of titles and abstracts. Finally, 3 GSE datasets, GSE49155, GSE33479 and GSE51852, were included ([@b29-ijo-54-05-1651],[@b30-ijo-54-05-1651]). The distribution of CASC9 expression and its ability to discriminate between LUSC and non-cancer tissue in each GSE dataset are displayed in [Fig. 2](#f2-ijo-54-05-1651){ref-type="fig"}. A flowchart of the selection process for appropriate microarray chips is illustrated in [Fig. 3](#f3-ijo-54-05-1651){ref-type="fig"}. No study from the literature survey was included in the final selection. The in-house RT-qPCR, TCGA and the included GEO microarray data were merged into a large pool containing 574 LUSC cases and 182 non-cancer cases for the integrated meta-analysis. Information on the three cohorts is listed in [Table III](#tIII-ijo-54-05-1651){ref-type="table"}. As demonstrated in [Fig. 4A](#f4-ijo-54-05-1651){ref-type="fig"}, the SMD generated from all the cohorts verified the overexpression of CASC9 in LUSC tissues, albeit with significant heterogeneity (SMD, 2.04; 95% CI, 1.27-2.81; I^2^=83.4%; P\<0.001). A subgroup analysis based on sample type and a sensitivity analysis failed to trace the source of the heterogeneity ([Fig. 4B and C](#f4-ijo-54-05-1651){ref-type="fig"}). No heterogeneity was observed in two studies on patient LUSC cells (I^2^=0.0%; P=0.678), in contrast with the large heterogeneity from the tissue data (I^2^=82.8%; P=0.001). The reason for this is that the two studies with different platforms in the cells subgroup were from the same GSE dataset (GSE49155). Begg\'s funnel plot indicated no publication bias (P=0.348). According to the evaluation with the SROC curves in [Fig. 5](#f5-ijo-54-05-1651){ref-type="fig"}, a high AUC (0.9125) revealed the marked ability of CASC9 in distinguishing LUSC from non-cancer tissues. The aggregated sensitivity, specificity, positive likelihood ratio, negative likelihood ratio and diagnostic odds ratio were 0.89, 0.83, 4.97, 0.18 and 33.80, respectively ([Fig. 5B-F](#f5-ijo-54-05-1651){ref-type="fig"}).

Cell line data of CASC9 expression from the CCLE
------------------------------------------------

The expression of CASC9 in each of the 191 LC cell lines was obtained and plotted in a heat map. The spectrum of colors ranged from red to green, reflecting a wide range of CASC9 expression from high to low ([Fig. 6A](#f6-ijo-54-05-1651){ref-type="fig"}).

Gene alteration of CASC9 in LUSC tissue from cBioPortal
-------------------------------------------------------

The alteration profiles of CASC9 from OncoPrint revealed that the CASC9 sequence was altered in 4 (2.2%) out of the 179 sequenced cases. The 4 cases of alteration all belonged to the category of amplification, i.e. multiple copies of the complete CASC9 gene were naturally occurring in 4 of the 179 sequenced cases ([Fig. 6B](#f6-ijo-54-05-1651){ref-type="fig"}).

Prediction of potential transcription factors for CASC9
-------------------------------------------------------

Based on the prediction results from LncMAP, 3 transcription factors, including Fos-related antigen 2 (FOSL2), SWI/SNF complex subunit SMARCC2, and transcription factor COE1 (EBF1), are likely to be involved in the regulatory effect of CASC9 on downstream molecules, including diacylglycerol kinase a, transient receptor potential cation channel subfamily V member 4, ankyrin repeat domain-containing protein SOWAHC, semaphorin-3G and DNA-binding protein Ikaros ([Table IV](#tIV-ijo-54-05-1651){ref-type="table"}). No prediction results of transcription factors associated with CASC9 were produced by other online programs. The correlation analyses demonstrated a positive correlation between FOSL2 and CASC9 expression (r=0.126; P=0.0046) and a negative correlation with EBF1 (r=−0.129; P=0.0038) ([Fig. 6C](#f6-ijo-54-05-1651){ref-type="fig"}). No significant correlations between SMARCC2 and CASC9 were observed (data not shown).

In vitro experiments
--------------------

The transfection efficiency of the 4 selected CASC9 siRNAs was \>80% at 96 h, as determined by RT-qPCR. It can be observed that CASC9 mRNA expression was obviously lower in CASC9 siRNA group than in scrambled siRNA group and blank control at 48, 72 and 96 h ([Fig. S2](#SD1-ijo-54-05-1651){ref-type="supplementary-material"}). [Fig. 7](#f7-ijo-54-05-1651){ref-type="fig"} illustrates the behavioral changes in LUSC cells caused by the siRNA knockdown of CASC9 in terms of cell viability and proliferation. The viability of the H226 cells in the CASC9 siRNA group decreased significantly after 48 and 72 h (both P\<0.001), while no significant change of cell viability occurred in H226 cells among the mock control (P=0.9821) and scrambled siRNA group (P=0.8790) at 72 h ([Fig. 7A](#f7-ijo-54-05-1651){ref-type="fig"}). Similarly, compared with the mock and scrambled siRNA controls, a substantial decrease in the cell proliferation of H226 cells of CASC9 siRNAs group was recorded using the MTS tetrazolium assay at 48 (P\<0.01) and 72 h (P\<0.001) ([Fig. 7B](#f7-ijo-54-05-1651){ref-type="fig"}).

Functional enrichment analysis of genes co-expressed with CASC9
---------------------------------------------------------------

With the aid of GEPIA, 200 genes were identified to be co-expressed with CASC9. An enrichment analysis of the 200 genes indicated 16 terms of biological processes and pathways significantly associated with them ([Table V](#tV-ijo-54-05-1651){ref-type="table"}; [Fig. 8](#f8-ijo-54-05-1651){ref-type="fig"}). Among the 16 significant terms, the top 3 biological processes were \'cell-cell junction organization\', \'desmosome organization\' and \'epidermis development\', and the top 3 pathways were \'Hippo signaling pathway\', \'pathogenic *Escherichia coli* infection\', and \'PID HIF1 TF pathway\' (all P\<0.01).

Associations between CASC9 and adjacentprotein-coding genes
-----------------------------------------------------------

Location-based displays (chromosome 8, 75,686,308-76,686,308) in the Ensemble Genome Browser unfolded the positional associations between CASC9 and adjacent protein-coding genes. Two such genes, cysteine-rich secretory protein LCCL domain-containing 1 (CRISPLD1; chromosome 8, 75,896,750-75,946,793) and hepatocyte nuclear factor 4-γ (HNF4G; chromosome 8, 76,320,271-76,476,562), were located 188,846 bp downstream and 129,575 bp upstream of CASC9 (chromosome 8, 76,135,639-76,190,696), respectively ([Fig. 9](#f9-ijo-54-05-1651){ref-type="fig"}). Correlation analyses indicated positive relationships between CASC9 and CRISPLD1 (r=0.269, P\<0.001) or HNF4G expression (r=0.196; P\<0.001) ([Fig. 6C](#f6-ijo-54-05-1651){ref-type="fig"}).

Discussion
==========

There is a large amount of evidence that lncRNAs are involved in the development of human cancer, with their regulatory effect on gene expression. Therefore, identifying tumor-associated lncRNAs and investigating the role of these molecules in the onset and progression of human cancer may facilitate the discovery of novel diagnostic and therapeutic biomarkers for LUSC.

The present study concentrated on CASC9, a cancer-associated lncRNA with carcinogenic function in several types of human cancer that has not been studied in LUSC. The expression level of CASC9 between LUSC and non-cancer tissue was first examined through RT-qPCR. The results demonstrated that CASC9 is overexpressed in LUSC tissue compared with non-cancer tissues. The statistical analysis of TCGA data and the integrated meta-analysis also reported significantly elevated CASC9 expression in LUSC tissues, supporting the RT-qPCR data. One of the highlights of the present study lies in the integrated meta-analysis incorporating in-house RT-qPCR, TCGA and GEO data. Evaluating the expression of CASC9 between LUSC and non-cancer tissues with the combined methods of data excavation from various public databases balanced the limited sample size of the clinical specimens obtained for the present study to a certain extent. The results of the analysis of the association between CASC9 expression and the clinicopathological parameters of LUSC imply that upregulated CASC9 may promote the malignant development of LUSC. The ROC and SROC curves for TCGA data reflected the capacity of CASC9 to distinguish LUSC from non-cancer tissues. These findings suggest that CASC9 may be applied as a therapeutic target for LUSC patients.

To gain deeper insights into the oncogenic influence of CASC9 on LUSC, *in vitro* experiments were performed investigating its functional role of CASC9 in this disease. Knockdown of CASC9 significantly diminished the viability and proliferation of H226 cells. This provided indirect evidence reinforcing the effect of CASC9 on the viability and growth of LUSC cells. Previous studies have probed into the influence of CASC9 on the cell growth in other cancer types, including ESCC and LUAD ([@b19-ijo-54-05-1651],[@b31-ijo-54-05-1651]). The study conducted by Wu *et al* ([@b31-ijo-54-05-1651]) demonstrated the negative correlation between CASC9 and programmed cell death protein 4 (PDCD4) in ESCC. PDCD4 is a tumor suppressor gene that participates in the regulation of apoptosis, proliferation and the cell cycle ([@b32-ijo-54-05-1651]-[@b34-ijo-54-05-1651]). Wu *et al* ([@b31-ijo-54-05-1651]) further proposed that CASC9 may downregulate PDCD4 expression by recruiting histone-lysine N-methyltransferase EZH2 to augment the proliferative ability of ESCC. It was hypothesized that the regulatory association between CASC9 and PDCD4 is be a possible explanation for the effect of CASC9 on the viability and proliferation of LUSC cells.

Following the *in vitro* experiments, the molecular mechanism of CASC9 in LUSC was investigated. The 2.2% incidence of naturally occurring gene duplication of CASC9 in LUSC samples was consistent with the upregulation of this lncRNA, providing a possible explanation for its overexpression in this cancer type. Since the functions of lncRNAs are dependent on binding to proteins ([@b35-ijo-54-05-1651],[@b36-ijo-54-05-1651]), a functional enrichment analysis of genes co-expressed with CASC9 is conducive to comprehending the molecular basis of CASC9-associated carcinogenesis of LUSC. From the annotation results, the top biological processes significantly clustered with the genes co-expressed with CASC9 were mainly associated with the epithelial-mesenchymal transition (EMT). Gao *et al* ([@b37-ijo-54-05-1651]) reported that CASC9 promotes ESCC proliferation and metastasis by modulating the EMT signaling pathway. The combination of the functional annotation results from the present study and the literature search suggest that CASC9 is involved in the dysregulation of the EMT process in LUSC. Apart from the aforementioned biological processes, the functional enrichment analysis revealed significantly assembled pathways, including the Hippo signaling and mitogen-activated protein kinase (MAPK)6/MAPK4 signaling pathways, which serve roles in the promotion or suppression of tumors ([@b38-ijo-54-05-1651],[@b39-ijo-54-05-1651]). It is speculated that CASC9 contributes to the initiation and progression of LUSC by participating in these biological processes and pathways. Other noteworthy aspects of the CASC9-centered tumorigenesis of LUSC are its upstream mediators and adjacent protein-coding genes. Potential factors that regulated the transcriptional activity of CASC9 were searched in a number of online programs. However, only lncRNAMap provided prediction results of CASC9-associated downstream transcription factors and mRNAs. Two of the predicted transcription factors were linked to NSCLC. The abnormal expression of SMARCC2 was discovered in squamous NSCLC tissue, and FOSL2 is required for transforming growth factor p1-induced migration in NSCLC ([@b40-ijo-54-05-1651],[@b41-ijo-54-05-1651]). The other transcription factor, EBF1, is a B-lineage transcriptional regulator involved in B-cell acute lymphoblastic leukemia ([@b42-ijo-54-05-1651]). Although only EBF1 expression was negatively correlated with CASC9 expression in LUSC, and none of the predicted transcription factors or mRNAs were confirmed in the literature search to be targeted by CASC9, these predicted downstream molecules hold important implications for the pathogenesis of LUSC. The association between CASC9 and adjacent protein-coding genes was also analyzed and CASC9 expression was positively correlated with two such genes, CRISPLD1 and HNF4G. Notably, HNF4G was reported in a previous study to serve an oncogenic role in LC by promoting cell proliferation ([@b43-ijo-54-05-1651]). Therefore, it was hypothesized that CASC9 modulates the expression of HNF4G or interacts with it to affect the occurrence and progression of LUSC. Additionally, CASC9 has been reported to enhance the malignant potential of human cancer types, including breast cancer, hepatocellular carcinoma and ESCC, by interacting with numerous target genes, such as EZH2, heterogeneous nuclear ribonucleoprotein L and laminin subunit γ-2 ([@b44-ijo-54-05-1651]-[@b46-ijo-54-05-1651]). Although these target genes were not revealed in the bioinformatics analysis of the present study, the association between them and CASC9 in LUSC is also worth exploring in future studies.

Although certain notable findings have been revealed, the limitations of the present study lie in the following aspects: Only the discernment capacity of CASC9 to distinguish LUSC from non-cancer tissues was assessed, and there was not sufficient evidence to support its diagnostic value in this disease. The serum CASC9 levels in patients should be investigated in future experiments for the evaluation of the diagnostic significance. Additionally, in the *in vitro* experiments, only CASC9 knockout was conducted. To comprehensively investigate the influence of CASC9 on the biological function of LUSC cells, overexpression experiment should also be performed. Furthermore, using \>3 types of cells lines in the *in vitro* experiment would be more conclusive than a single cell line. Further *in vitro* and *in vivo* experiments are required to verify the influence of CASC9 on the aforementioned biological processes and pathways, as well as the targeting regulatory association between CASC9 and the predicted transcription factors or adjacent protein-coding genes.

In summary, the present study revealed the overexpression and clinicopathological significance of CASC9 in LUSC for the first time. The role of CASC9 as a cancer-promoting factor in LUSC may be accomplished by strengthening the viability and proliferation capacity of the tumor cells. A functional enrichment analysis of co-expressed genes and the correlation between the expression of CASC9 and predicted transcription factors or adjacent protein-coding genes inferred a potential molecular mechanism of CASC9-associated LUSC tumorigenesis.
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![Flowchart of the design of the current study. SMD, standardized mean difference; SROC, summarized receiver operating characteristic; TCGA, The Cancer Genome Atlas; GEO, Gene Expression Omnibus; LUSC, refers to lung squamous cell carcinoma; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; GEPIA, Gene Expression Profiling Interactive Analysis; CASC9, cancer susceptibility candidate 9.](IJO-54-05-1651-g00){#f1-ijo-54-05-1651}

![CASC9 expression and its diagnostic ability in LUSC for all the investigated datasets. The scatter plots (left panels) and wiring diagrams (middle panels) present the differential expression levels of CASC9 in LUSC samples and non-cancer samples for (A) RT-qPCR, (B) TCGA and GEO microarray (C) GSE33479, (D) GSE49155 (GPL10999), (E) GSE49155 (GPL11154) and (F) GSE51852 data. The ROC curves (right panels) demonstrate the capacity of CASC9 to identify LUSC from normal samples. CASC9, cancer susceptibility candidate 9; LUSC, lung squamous cell carcinoma; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; TCGA, The Cancer Genome Atlas; GEO, Gene Expression Omnibus; ROC, receiver operating characteristic; AUC, area under the curve.](IJO-54-05-1651-g01){#f2-ijo-54-05-1651}

![Flowchart of the integrated meta-analysis data selection. A total of 2,921 and 1,860 studies appeared as the initial records from the GEO and ArrayExpress, respectively. Following the screening of titles and abstracts, 2,836 and 1,851 studies from GEO and ArrayExpress, respectively, were excluded. Finally, 3 GSE datasets were enrolled for the meta-analysis following the process of full-text reviewing. GEO, Gene Expression Omnibus.](IJO-54-05-1651-g02){#f3-ijo-54-05-1651}

![Integrated meta-analysis for CASC9 expression in lung squamous cell carcinoma. (A) The forest plot for the integrated meta-analysis. (B) Forest plot of subgroup analysis based on sample type. (C) Sensitivity analysis. (D) Begg\'s funnel plot. CASC9, cancer susceptibility candidate 9; SMD, standardized mean difference; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; TCGA, The Cancer Genome Atlas; CI, confidence interval; SE, standard error.](IJO-54-05-1651-g03){#f4-ijo-54-05-1651}

![SROC curves and pooled diagnostic indices for the integrated meta-analysis. (A) The AUC of the SROC curves was 0.9520, indicating a significant differentiating capacity of CASC9 in LUSC. (B) The pooled sensitivity for the included studies was 0.93 (0.91-0.95). (C) The pooled specificity was 0.87 (0.81-0.91). (D) The pooled positive LR was 6.78 (2.37-19.36). (E) The pooled negative LR was 0.11 (0.05-0.25). (F) The pooled diagnostic OR was 66.23 (17.54-250.11). SROC, summarized receiver operating characteristic; AUC, area under the curve; SE, standard error; Q, quartile; CI, confidence interval; df, degrees of freedom; LR, likelihood ratio; OR, odds ratio.](IJO-54-05-1651-g04){#f5-ijo-54-05-1651}

![CASC9 expression heat-map, gene alteration prediction and correlation analysis. (A) Heat-map of CASC9 expression in 191 lung cancer cell lines arranged from high to low, corresponding to the spectrum of colors from red to green. (B) A total of 4 (2.2%) incidences of CASC9 amplification were revealed in 179 sequenced cases. (C) Correlation between the expression of CASC9 and predicted transcription factors or adjacent protein-coding genes. CASC9 was positively correlated with FOSL2 (r=0.126; P=0.0046), CRISPLD1 (r=0.269; P\<0.001) and HNF4G (r=0.196; P\<0.001), and negatively correlated with EBF1 (r=−0.129; P=0.0038). CASC9, cancer susceptibility candidate 9; GISTIC, genomic identification of significant targets in cancer; FOSL2, Fos-related antigen 2; EBF1, transcription factor COE1; CRISPLD1, cysteine-rich secretory protein LCCL domain-containing 1; HNF4G, hepatocyte nuclear factor 4-γ.](IJO-54-05-1651-g05){#f6-ijo-54-05-1651}

![Cell viability and proliferation measurements following CASC9 knockdown. The viability and proliferation of H226 cells with siRNA down- regulation of CASC9 were measured using fluorimetric resorufin viability and MTS tetrazolium assays. (A) The influence of CASC9 silencing on (A) the viability and (B) the proliferation of H226 cells. The data are normalized to the blank control at the corresponding time point, and are presented as the average of three experiments and the standard deviation (error bars). \*\*P\<0.01 and \*\*\*P\<0.001, compared with the mock control or scrambled siRNAs groups at the same time point. CASC9, cancer susceptibility candidate 9; siRNA, small interfering RNA.](IJO-54-05-1651-g06){#f7-ijo-54-05-1651}

![GO analysis and pathway enrichment. (A) Nodes in the concentric circle graph represent co-expressed genes clustered in specific biological process terms. The inner sectors with larger size and darker color represented more significant enrichment. (B) Ribbons with different colors corresponded to different enriched pathways terms from Metascape. GO, gene ontology.](IJO-54-05-1651-g07){#f8-ijo-54-05-1651}

![Genomic locations of CASC9 and adjacent protein-coding genes. CRISPLD1 (chromosome 8, 75,896,750-75,946,793) and HNF4G (chromosome 8, 76,320,271-76,476,562) were 188,846 bp downstream and 129,575 bp upstream from CASC9 (chromosome 8, 76,135,639-76,190,696), respectively. CASC9, cancer susceptibility candidate 9; CRISPLD1, cysteine-rich secretory protein LCCL domain-containing 1; HNF4G, hepatocyte nuclear factor 4-γ.](IJO-54-05-1651-g08){#f9-ijo-54-05-1651}

###### 

Clinicopathological variables and CASC9 expression in lung squamous cell carcinoma data from The Cancer Genome Atlas.

  Clinicopathological feature                                n     CASC9 expression   P-value   
  ---------------------------------------------------------- ----- ------------------ --------- ---------
  Tissue type                                                                         10.921    \<0.001
   Cancer                                                    501   4.420±1.528                  
   Normal                                                    49    0.190±0.282                  
  Sex                                                                                 −2.181    0.029
   Male                                                      370   4.503±1.472                  
   Female                                                    131   4.187±1.627                  
  Age, years[a](#tfn1-ijo-54-05-1651){ref-type="table-fn"}                            −0.187    0.852
   \>60                                                      405   4.072±1.864                  
   \<60                                                      87    4.045±1.923                  
  Tumor location                                                                      −0.929    0.353
   Central                                                   145   4.179±1.845                  
   Peripheral                                                94    3.911±1.964                  
  Stage                                                                               −4.040    \<0.001
   I-II                                                      412   3.987±1.885                  
   III-IV                                                    85    4.795±1.396                  
  Distant metastasis                                                                  −2.843    0.004
   M0-MX                                                     489   4.043±1.889                  
   M1-M1b                                                    7     5.691±0.770                  
  Lymph node metastasis                                                               −2.064    0.039
   N0-NX                                                     325   4.328±1.546                  
   N1-N3                                                     176   4.592±1.457                  
  Primary tumor stage                                                                 −1.077    0.281
   T1-T2                                                     407   4.397±1.521                  
   T3-T4                                                     94    4.524±1.517                  
  Anatomical classification                                                           3.253     0.661
   Bronchial                                                 10    4.387±1.586                  
   L-lower                                                   77    4.356±1.772                  
   L-upper                                                   134   4.292±1.628                  
   R-lower                                                   107   4.118±1.834                  
   R-middle                                                  16    3.636±2.277                  
   R-upper                                                   139   3.834±2.048                  

Data available for 492 cases. Comparisons were performed using a Mann-Whitney test, with the exception of the anatomical classification, which was analyzed using a Kruskal-Wallis test. CASC9, cancel susceptibility candidate 9; SD, standard deviation; L, left; R, right.

###### 

Multivariate Cox regression analysis of clinical parameters and CASC9 expression in TCGA cohort of patients with lung squamous cell carcinoma.

  Variable[a](#tfn2-ijo-54-05-1651){ref-type="table-fn"}   HR (95% CI)            P-value
  -------------------------------------------------------- ---------------------- ---------
  CASC9 expression (high vs. low)                          1.308 (0.790-2.168)    0.297
  Sex                                                      1.177 (0.681-2.034)    0.560
  Age, years                                               0.480 (0.269-0.855)    0.013
  Tumor location                                           1.850 (1.080-3.169)    0.025
  Tumor stage                                              1.886 (0.991-3.590)    0.053
  Distant metastasis                                       2.382 (0.321-17.689)   0.396
  Lymph node metastasis                                    0.842 (0.492-1.441)    0.529
  Primary tumor stage                                      1.582 (0.843-2.971)    0.153
  Anatomical subdivision                                   1.024 (0.874-1.201)    0.768

The subcategories of the variables being compared are as listed in [Table I](#tI-ijo-54-05-1651){ref-type="table"}. CASC9, cancer susceptibility candidate 9; HR, hazard ratio; CI, confidence interval.

###### 

Basic, expression and diagnostic information of all datasets.

                                                        Cancer   Normal                                                 
  ---------- --------- --------------------- ---------- -------- ------------- ---- -------------- ----- ---- ---- ---- -------------------------
  GSE49155   Cells     Ooi *et al*, 2014     GPL10999   4        1.263±0.578   7    0.470±1.223    4     1    0    6    ([@b31-ijo-54-05-1651])
  GSE49155   Cells     Ooi *et al*, 2014     GPL11154   6        5.976±7.863   7    0.028±0.070    6     1    0    6    ([@b31-ijo-54-05-1651])
  GSE33479   Tissues   N/A                   GPL6480    14       3.706±2.256   95   −0.415±1.908   13    18   1    77   
  GSE51852   Tissues   Arima *et al*, 2014   GPL6480    28       1.255±1.725   4    −4.824±0.231   26    0    2    4    ([@b32-ijo-54-05-1651])
  RT-qPCR    Tissues   Present study         N/A        20       2.771±0.974   20   1.397±0.857    15    3    5    17   \-
  TCGA       Tissues   N/A                   Seq-TPM    502      4.422±1.518   49   0.185±0.282    465   0    37   49   \-

N/A, not applicable; SD, standard deviation; TP, true positive; FP, false positive; FN, false negative; TN, true negative; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; TPM, transcripts per million reads.

###### 

Potential transcription factors and genes associated with CASC9 (lncRNA ID, ENSG00000249395) from LncMAP.

  TF ID               TF name   Gene ID           Gene name   Correlation coefficient (r) according to CASC9 expression   Score    P-value   FDR       
  ------------------- --------- ----------------- ----------- ----------------------------------------------------------- -------- --------- --------- ---------
  EN S G00000075426   FOSL2     ENSG00000065357   DGKA        0.513                                                       −0.002   0.995     \<0.001   \<0.001
  ENSG00000075426     FOSL2     ENSG00000111199   TRPV4       0.600                                                       −0.098   1.000     \<0.001   \<0.001
  ENSG00000075426     FOSL2     ENSG00000198142   SOWAHC      0.607                                                       −0.082   1.000     \<0.001   \<0.001
  ENSG00000139613     SMARCC2   ENSG00000010319   SEMA3G      0.079                                                       0.588    0.997     \<0.001   \<0.001
  ENSG00000164330     EBF1      ENSG00000185811   IKZF1       0.608                                                       0.135    0.995     \<0.001   \<0.001

CASC9, cancer susceptibility candidate 9; TF, transcription factor; FDR, false discovery rate; FOSL2, Fos-related antigen 2; SMARCC2, SWI/SNF complex subunit SMARCC2; EBF1, transcription factor COE1; DGKA, diacylglycerol kinase a; TRPV4, transient receptor potential cation channel subfamily V member 4; SOWAHC, ankyrin repeat domain-containing protein SOWAHC; SEMA3G, semaphorin-3G; IKZF1, DNA-binding protein Ikaros.

###### 

Metascape enrichment analysis for the co-expressed genes of cancer susceptibility candidate 9.

  GO ID           Category                  Term                                                                               Count of enriched genes   Log~10~(P)
  --------------- ------------------------- ---------------------------------------------------------------------------------- ------------------------- ------------
  GO:0045216      GO Biological Processes   \'Cell-cell junction organization\'                                                9                         −7.340
  GO:0002934      GO Biological Processes   \'Desmosome organization\'                                                         4                         −7.010
  GO:0008544      GO Biological Processes   \'Epidermis development\'                                                          13                        −6.630
  GO:0098609      GO Biological Processes   \'Cell-cell adhesion\'                                                             15                        −5.420
  hsa04390        KEGG Pathway              \'Hippo signaling pathway\'                                                        6                         −4.030
  GO:0060713      GO Biological Processes   \'Labyrinthine layer morphogenesis\'                                               3                         −3.960
  GO:0043516      GO Biological Processes   \'Regulation of DNA damage response, signal transduction by p53 class mediator\'   3                         −3.420
  GO:0030168      GO Biological Processes   \'Platelet activation\'                                                            5                         −3.100
  GO:0043616      GO Biological Processes   \'Keratinocyte proliferation\'                                                     3                         −3.020
  hsa05130        KEGG Pathway              \'Pathogenic *Escherichia coli* infection\'                                        3                         −2.650
  GO:0097193      GO Biological Processes   \'Intrinsic apoptotic signaling pathway\'                                          6                         −2.610
  M255            Canonical Pathways        \'PID HIF1 TF pathway\'                                                            3                         −2.420
  R-HSA-422356    Reactome Gene Sets        Regulation of insulin secretion                                                    3                         −2.190
  GO:0070848      GO Biological Processes   Response to growth factor                                                          9                         −2.130
  R-HSA-6798695   Reactome Gene Sets        Neutrophil degranulation                                                           7                         −2.110
  R-HSA-5687128   Reactome Gene Sets        MAPK6/MAPK4 signaling                                                              3                         −2.060

GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; MAPK, mitogen-activated protein kinase.

[^1]: Contributed equally
